This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Louisiana State University and Agricultural & Mechanical College, Ndsu-Research Foundation. Active years: 2024.
Company Filing History:
1 out of 838 
1 out of 145 
Years Active: 2024
Title: Mohiuddin Quadir: Innovator in Cancer Treatment Technologies
Introduction
Mohiuddin Quadir is a notable inventor based in Fargo, ND (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. His work focuses on developing advanced drug delivery systems that enhance the efficacy of chemotherapeutic agents.
Latest Patents
Mohiuddin Quadir holds a patent for "pH responsive drug conjugated nanocarriers." This invention relates to methods of treating cancer by administering a therapeutically effective dose of a chemotherapeutic agent, which is conjugated to a nanocarrier. The invention emphasizes the use of pH-sensitive nanocarriers that can improve the delivery and effectiveness of various chemotherapeutic drugs, including platinum-based pharmaceuticals and those from the Anthracycline family.
Career Highlights
Throughout his career, Mohiuddin Quadir has worked with esteemed institutions such as Louisiana State University and Agricultural & Mechanical College and North Dakota State University Research Foundation. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Mohiuddin has collaborated with Md Shenuarin Bhuiyan, working together on various projects that aim to advance cancer treatment methodologies. Their partnership has fostered innovation and has the potential to lead to further developments in the field.
Conclusion
Mohiuddin Quadir's contributions to cancer treatment through his patented technologies highlight his role as an influential inventor. His work continues to pave the way for advancements in drug delivery systems, ultimately benefiting patients in need of effective cancer therapies.